Approved indications: Plegisol, after buffering with 8.4% sodium bicarbonate and cooling, is indicated to induce temporary cardiac arrest (cardioplegia) during open‑heart surgery on cardiopulmonary bypass when the coronary circulation is isolated from the systemic circulation.

Off‑label uses: There are no well‑established FDA‑recognized off‑label indications; in practice, surgeons may individualize dosing schedules or combine Plegisol with other cardioplegic or cardioprotective agents as part of institutional protocols rather than as distinct labeled uses.

Efficacy expectations:

• Plegisol usually produces rapid diastolic arrest within seconds, providing a motionless, blood‑reduced operative field and lowering myocardial oxygen demand.
• When used correctly together with hypothermia and controlled ischemia, it helps preserve myocardial structure and function so that most hearts can resume effective beating after reperfusion, sometimes with brief pacing or defibrillation.
• Clinical outcomes are generally comparable to those with other crystalloid cardioplegic solutions; many centers also use blood cardioplegia, and the choice among solutions is driven mainly by surgeon experience, institutional practice, and specific patient or procedure factors.

Typical dosing and route: After 10 mL of 8.4% sodium bicarbonate is added to each 1000 mL of Plegisol and the mixture is cooled to about 4°C, the buffered solution is rapidly infused into the aortic root or directly into the coronary ostia during cardiopulmonary bypass at approximately 300 mL/m² per minute for 2–4 minutes to induce initial arrest, with repeat infusions at the same rate for about 2 minutes every 20–30 minutes or sooner if myocardial temperature rises or cardiac activity returns.

Administration details:

• Use only when the coronary circulation is isolated from the systemic circulation on cardiopulmonary bypass, and never as a conventional intravenous infusion.
• Ensure effective right‑heart venting so that large volumes of cardioplegic solution do not recirculate systemically, and continuously monitor ECG and myocardial temperature during cross‑clamp.
• Any additional agents added to the solution must be checked for compatibility, introduced under aseptic technique, mixed thoroughly, and the final admixture should not be stored beyond the 24‑hour limit after bicarbonate addition.

Special dosing instructions: There is no fixed maximum cumulative volume; total dose and timing are individualized by the surgical team based on body surface area, degree of hypothermia, duration of aortic cross‑clamping, and the heart’s electrical and mechanical response.

Missed‑dose guidance: Missed doses are not applicable, as Plegisol is administered only intraoperatively and dosing is adjusted in real time by the surgeon and perfusion team.

Overdose management: If excessive volumes are instilled or significant systemic exposure is suspected, the team should stop or reduce the infusion, optimize venting and bypass circuit management, correct electrolyte and acid–base disturbances, treat hypotension and arrhythmias, and provide supportive hemodynamic care until cardiovascular status stabilizes.

Common perioperative effects: Because Plegisol is used only during open‑heart surgery on bypass, observed effects largely reflect the procedure and cardioplegia itself, such as transient ECG changes, short‑lived arrhythmias when the heart is restarted, and mild shifts in potassium and magnesium if some solution mixes into the systemic circulation.

Serious or rare adverse effects:

• Myocardial infarction, significant arrhythmias including ventricular fibrillation, and delayed or absent return of spontaneous heartbeat after cardioplegia, which may require electrical defibrillation and inotropic or vasopressor support.
• Severe hypotension and metabolic acidosis if very large volumes of cardioplegic solution are allowed to recirculate through the bypass pump without adequate right‑heart venting, due to excess potassium and magnesium entering the systemic circulation.
• Overzealous local instillation can excessively dilate intramyocardial vessels and lead to myocardial tissue edema.

Warnings and precautions: Plegisol must never be given by standard intravenous infusion; it is for intra‑arterial cardiac instillation only after adding the specified 10 mL of 8.4% sodium bicarbonate per 1000 mL, cooling to about 4°C, and using within 24 hours of mixing, and it should be administered only by teams experienced in cardiopulmonary bypass. Safety and effectiveness in pediatric patients are not established; in pregnancy it should be used only if clearly needed, and no specific dose adjustments are defined for elderly or for kidney or liver impairment because systemic exposure is limited when the coronary circulation is isolated.

Relative safety compared with alternatives: When prepared and delivered correctly into the isolated coronary circulation with appropriate monitoring and venting, Plegisol’s safety profile is similar to that of other high‑potassium crystalloid cardioplegic solutions, with most serious problems arising from technical issues, large systemic exposure, or underlying patient risk rather than from the solution itself.

Reporting side effects and finding safety updates: Clinicians should report serious or unexpected adverse events through their institution, to the manufacturer, and to the U.S. FDA MedWatch adverse event reporting program (online or by phone), and should consult the latest prescribing information for current warnings and safety communications.

Drug and additive interactions: Because Plegisol is delivered into the isolated coronary circulation during bypass, clinically important systemic interactions with other prescription or over‑the‑counter drugs, foods, alcohol, or imaging contrast agents are minimal; however, substances added directly to the Plegisol bag (such as other electrolytes, substrates, or drugs) may be physically or chemically incompatible and should only be used after compatibility review, careful aseptic addition, thorough mixing, and without prolonged storage.

Conditions and co‑medications requiring caution: Extra caution is warranted in patients with pre‑existing electrolyte abnormalities, conduction disturbances, or severe ventricular dysfunction, and in situations where large volumes of cardioplegia may enter the systemic circulation, particularly when patients are also receiving therapies that affect potassium, magnesium, or hemodynamics (for example, inotropes, vasopressors, or antiarrhythmics).

Monitoring needs:

• Continuous ECG monitoring to document onset of arrest, detect ischemic changes, and guide defibrillation or pacing on reperfusion.
• Frequent measurement of myocardial temperature to maintain adequate hypothermia within the target range defined by the institutional protocol.
• Intraoperative monitoring of systemic blood pressure, acid–base status, and electrolytes on bypass, especially if substantial volumes of Plegisol have entered the pump reservoir.

General precautions: Plegisol should be used only by teams experienced in open‑heart surgery and cardiopulmonary bypass, the solution must be clear with an intact container before use, any unused portion should be discarded, and label directions regarding buffering, cooling, route of administration, and time limits after mixing must be strictly followed.

Q: What is Plegisol and why is it used during my heart surgery?
A: Plegisol is a specially formulated salt solution used during open‑heart surgery to safely and temporarily stop your heart, allowing the surgeon to work on a still, protected heart while a heart‑lung machine circulates your blood.

Q: How will Plegisol be given to me?
A: During surgery, after you are under anesthesia and on the heart‑lung machine, the surgical team infuses cold, buffered Plegisol directly into the arteries that supply your heart (through the aortic root or coronary openings), never through a standard IV.

Q: What happens to my heart after Plegisol is used?
A: Once the surgical repair is finished and blood flow and temperature are gradually restored, your heart is rewarmed, Plegisol is washed out, and the team stimulates the heart to beat again, sometimes with a brief electrical shock or pacing if needed.

Q: What are the main risks of Plegisol?
A: The main risks relate to open‑heart surgery and cardioplegia in general—such as heart rhythm problems, low blood pressure, or heart damage—especially if large volumes of the solution enter the general circulation, which is why dosing, venting, and monitoring are tightly controlled by the surgical team.

Q: Is Plegisol used in children or during pregnancy?
A: Safety and effectiveness of Plegisol in pediatric patients have not been established, and in pregnant patients it is used only if clearly needed during life‑saving cardiac surgery, with decisions made by the heart team based on risks and benefits.